Hospital Santa Maria Della Misericordia
- Address
- lock Available on a paid plan
Oncology and Hematologic Malignancies
At Hospital Santa Maria Della Misericordia, a major share of research focuses on neoplasms and blood cancers, with studies in non-small cell lung cancer, melanoma, lymphoma, leukemia, multiple myeloma, and breast cancer. The trials are largely aimed at testing new cancer therapies, improving treatment combinations, and understanding how to better control disease recurrence and progression.
- Research in advanced and resected lung cancer, including targeted and immunotherapy approaches
- Studies in acute myeloid leukemia, acute lymphoblastic leukemia, and other leukemias with risk-adapted treatment strategies
- Trials in lymphoma, multiple myeloma, and related hematologic cancers to improve response and durability of benefit
- Investigations in melanoma and breast cancer focused on better disease control after standard treatment
Overall, the site supports a broad and active oncology program that combines precision medicine, immunotherapy, and new treatment options for both solid tumors and blood cancers.
Cardiovascular and Metabolic Research
The site also conducts important trials in cardiovascular diseases and nutritional and metabolic diseases, especially heart failure, atrial fibrillation, atherosclerotic cardiovascular disease, type 2 diabetes, obesity, and elevated lipoprotein(a). These studies aim to evaluate whether newer treatments can reduce complications, improve long-term outcomes, and lower the burden of chronic disease.
- Trials in heart failure and related cardiovascular conditions to reduce events and improve clinical stability
- Research on atrial fibrillation and coronary disease to refine prevention and treatment strategies
- Studies in obesity, type 2 diabetes, and lipid disorders to address cardiometabolic risk
- Work on lipoprotein(a) and atherosclerosis to better understand cardiovascular risk reduction
This therapeutic area reflects a strong interest in long-term disease prevention and in treatments that can support better heart and metabolic health.
Neurology, Eye Disease, and Immune-Mediated Conditions
Clinical research at the site spans nervous system diseases, eye diseases, and immune system diseases, including Alzheimer’s disease, migraine, multiple sclerosis, age-related macular degeneration, atopic dermatitis, prurigo nodularis, and rheumatoid arthritis. The purpose of these trials is often to improve symptom control, slow disease worsening, or test new options for chronic inflammatory and degenerative disorders.
- Studies in Alzheimer’s disease and cognitive impairment focused on slowing decline and supporting brain health
- Trials for migraine and headache disorders aimed at prevention and better symptom relief
- Research in age-related macular degeneration and other eye conditions to preserve vision
- Immune and inflammatory disease studies in atopic dermatitis, rheumatoid arthritis, and related skin and joint disorders
Within the Department of Medicine and Surgery, this work highlights a broad commitment to improving both quality of life and disease control in chronic conditions.
Respiratory, Skin, and Multisystem Disease Studies
The research portfolio at Hospital Santa Maria Della Misericordia also includes respiratory tract diseases, skin and connective tissue diseases, and other complex inflammatory conditions such as idiopathic pulmonary fibrosis, small-cell lung cancer, hidradenitis suppurativa, acne vulgaris, and systemic sclerosis. These trials are designed to evaluate new therapies, improve disease management, and address conditions with limited treatment options.
- Research in idiopathic pulmonary fibrosis aimed at slowing lung function decline
- Studies in small-cell lung cancer and other respiratory cancers to improve treatment effectiveness
- Trials in hidradenitis suppurativa, acne vulgaris, and related skin disorders to reduce inflammation and symptoms
- Investigations in systemic sclerosis and other multisystem immune conditions to better manage chronic disease burden
With many investigators contributing across these areas, the site supports a diverse portfolio that connects oncology, inflammation, and chronic organ disease research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 12 therapeutic areas and 15 of 337 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 328 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 56 by active trials.
lock +55 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG13trials
lock +41 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Santa Maria Della Misericordia
lock Showing 1 of 209 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 337 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 21 | Unknown | 2018-08-09 | 2026-04-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.